Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ARDOXSO
- Development stage
- Unknown
- Lead developer
- AVEM HealthCare
- Modality
- Cell Therapies, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
ARDOXSO is an exosome-based therapy derived from mesenchymal stem cells (MSCs), developed by AVEM HealthCare. It is designed to treat severe respiratory conditions, specifically COVID-19 associated acute respiratory distress syndrome (ARDS) and viral pneumonia. The therapy leverages the natural immunomodulatory and anti-inflammatory properties of MSC-derived extracellular vesicles. These exosomes contain bioactive molecules such as proteins, lipids, and RNA that can modulate the host immune response, potentially mitigating the "cytokine storm" often seen in severe COVID-19 cases. By reducing pro-inflammatory cytokines and promoting tissue repair, ARDOXSO aims to improve lung function and reduce mortality in critically ill patients.
- Brand names
- ARDOXSO
- Other names
- mesenchymal stem cell-derived exosomesMSC-exosomesMSC-derived exosomes
02
Targets
FASN (Fatty acid synthase)IL10RA (Interleukin-10 Receptor)NLRP3 (Nod-like receptor family pyrin domain-containing protein 3)PDCD1 (Programmed cell death protein 1 receptor)TGFBR (TGF-beta receptor)
Beyond the preview
Go deeper on ARDOXSO.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ARDOXSO.